The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.
Status: Recruiting | Phase III
Official Title: A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (BI-SHRNAFURIN and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing’s Sarcoma
Study Purpose: To test the safety and efficacy of Vigil when given with standard chemotherapy. To determine if Vigil given with standard chemotherapy prevents or delays tumor growth or shrinks an existing tumor. Learn more.
Status: Recruiting | Phase Ib
Official Title: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-Squamous Non-Small Cell Lung Cancer
Study Purpose: The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with sarcoma prior to surgery. Learn more.